These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9681686)

  • 1. Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry.
    Hildenbrand R; Glienke W; Magdolen V; Graeff H; Stutte HJ; Schmitt M
    Histochem Cell Biol; 1998 Jul; 110(1):27-32. PubMed ID: 9681686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of immunolocalization of the urokinase receptor expression in ductal carcinoma in situ of the breast: comparison with detection by non-isotopic in-situ hybridization.
    Hildenbrand R; Leitz M; Magdolen V; Luther T; Albrecht S; Graeff H; Stutte HJ; Bleyl U; Schmitt M
    Histopathology; 2000 Jun; 36(6):499-504. PubMed ID: 10849091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
    Fisher JL; Field CL; Zhou H; Harris TL; Henderson MA; Choong PF
    Breast Cancer Res Treat; 2000 May; 61(1):1-12. PubMed ID: 10930085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor.
    Nielsen BS; Rank F; Illemann M; Lund LR; Danø K
    Int J Cancer; 2007 May; 120(10):2086-95. PubMed ID: 17290405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
    Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
    Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urokinase receptor-associated protein (uPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells.
    Schnack Nielsen B; Rank F; Engelholm LH; Holm A; Danø K; Behrendt N
    Int J Cancer; 2002 Apr; 98(5):656-64. PubMed ID: 11920633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
    Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
    Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies.
    Carriero MV; Franco P; Del Vecchio S; Massa O; Botti G; D'Aiuto G; Stoppelli MP; Salvatore M
    Cancer Res; 1994 Oct; 54(20):5445-54. PubMed ID: 7923178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry.
    Kennedy S; Duffy MJ; Duggan C; Barnes C; Rafferty R; Kramer MD
    Br J Cancer; 1998 May; 77(10):1638-41. PubMed ID: 9635840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
    Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
    Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
    Mahanivong C; Yu J; Huang S
    Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.
    Nordengren J; Pilka R; Noskova V; Ehinger A; Domanski H; Andersson C; Høyer-Hansen G; Hansson SR; Casslén B
    Mol Hum Reprod; 2004 Sep; 10(9):655-63. PubMed ID: 15243126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer.
    Nielsen BS; Sehested M; Timshel S; Pyke C; Danø K
    Lab Invest; 1996 Jan; 74(1):168-77. PubMed ID: 8569179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma.
    Xu Y; Hagege J; Doublet JD; Callard P; Sraer JD; Ronne E; Rondeau E
    Hum Pathol; 1997 Feb; 28(2):206-13. PubMed ID: 9023404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
    Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
    Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasminogen activator system localization in 60 cases of ductal carcinoma in situ.
    Hurd TC; Sait S; Kohga S; Winston J; Martinick M; Saxena R; Lankes H; Markus G; Harvey S; Gibbs JF
    Ann Surg Oncol; 2007 Nov; 14(11):3117-24. PubMed ID: 17701256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
    Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
    Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunologic detection of the cellular receptor for urokinase plasminogen activator.
    Mizukami IF; Garni-Wagner BA; DeAngelo LM; Liebert M; Flint A; Lawrence DA; Cohen RL; Todd RF
    Clin Immunol Immunopathol; 1994 Apr; 71(1):96-104. PubMed ID: 8137563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.
    Christensen L; Wiborg Simonsen AC; Heegaard CW; Moestrup SK; Andersen JA; Andreasen PA
    Int J Cancer; 1996 May; 66(4):441-52. PubMed ID: 8635858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.